Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort

Sponsor

Bionano Genomics (Industry)

Overall Status

Recruiting

CT.gov ID

NCT05295277

Collaborator

University of Rochester (Other), Columbia University (Other), Greenwood Genetic Center (Other), Praxis Genomics (Other), Augusta University (Other), Medical College of Wisconsin (Other), University of Iowa (Other)

1,000

Enrollment

Locations

Anticipated Duration (Months)

125

Patients Per Site

2.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this research use only (RUO) study is to detect genomic structural variants (SVs) in human DNA by Optical Genome Mapping (OGM) using the Bionano Genomics Saphyr system. SVs are a type of genetic alternation that includes deletions, duplications, and both balanced and unbalanced rearrangements (ex: inversions or translocations), as well as specific repeat expansions and contractions. The results of OGM analysis will be compared to prior clinical genetic test results to determine how OGM compares to current standard of care (SOC) clinical test methods such as chromosomal microarray analysis (CMA), karyotyping, Southern blot analysis, polymerase chain reaction (PCR), fluorescence in situ hybridization (FISH), and/or next generation sequencing (NGS), etc.

Condition or Disease	Intervention/Treatment	Phase
Developmental Disability Intellectual Disability Autism Spectrum Disorder Congenital Anomaly Fragile X Syndrome Facioscapulohumeral Muscular Dystrophy 1	Other: Standard of care genetic testing group

Detailed Description

Optical genome mapping (OGM) is an emerging next-generation cytogenomic tool that enables a comprehensive analysis of structural variants (SVs) in the genome. OGM, in its current iteration, is performed on the Saphyr system, which is developed and marketed by Bionano Genomics (San Diego, CA). OGM employs imaging of ultra-long DNA molecules (>150 kbp) that are labeled at a unique 6 base-pair sequence motif (CTTAAG) that occurs throughout the genome. The images of the labeled DNA molecules are used to generate a de novo assembly that can be compared to a reference genome to identify all classes of SVs, such as deletions, duplications, balanced/ unbalanced genomic rearrangements (insertions, inversions, and translocations), and repeat array expansions/contractions). In addition, a separate coverage-based algorithm enables the detection of genome-wide copy number analysis (similar to CMA), and the absence of heterozygosity (AOH) analysis. In the same assay, a concurrent or stepwise data analysis pipeline allows for sizing pathogenic CGG repeat expansions (consistent with fragile X syndrome) as well as D4Z4 repeat contractions which are consistent with facioscapulohumeral muscular dystrophy type 1 (FSHD1). Recently, in several studies, OGM has demonstrated excellent concordance with standard-of-care testing. Importantly, the OGM workflow can provide results within three-five days.

The aim of this double-blinded, multi-site, retrospective, observational, Institutional Review Board (IRB)-approved study is to evaluate the concordance of structural variant detection by OGM compared to standard of care tests (such as CMA, karyotyping, Southern blot analysis, PCR, FISH, and/or NGS, etc.), in a large cohort containing a variety of SVs including aneuploidies, intragenic and contiguous deletions, duplications, balanced and unbalanced translocations, inversions, isochromosomes, ring chromosomes, repeat expansions, repeat contractions, and more. This study is also designed to assess the sensitivity, specificity, and reproducibility of OGM analysis conducted at multiple sites, by numerous operators, and on different Saphyr instruments. Consensus testing and interpretation protocols were developed and implemented at all sites.

Study Design

Study Type:

Observational

Anticipated Enrollment :

1000 participants

Observational Model:

Cohort

Time Perspective:

Retrospective

Official Title:

Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort

Actual Study Start Date :

Nov 30, 2020

Anticipated Primary Completion Date :

Mar 31, 2024

Anticipated Study Completion Date :

Jun 30, 2024

Arms and Interventions

Arm	Intervention/Treatment
Standard of care genetic testing group Individuals with genomic test results from a standard of care (SOC) test (such as CMA, karyotyping, Southern blot analysis, PCR, FISH, and/or NGS, etc.) will be enrolled in the study to compare the SOC result to results from optical genome mapping.	Other: Standard of care genetic testing group N/A - no intervention as this is an observational study.

Arm

Intervention/Treatment

Standard of care genetic testing group

Individuals with genomic test results from a standard of care (SOC) test (such as CMA, karyotyping, Southern blot analysis, PCR, FISH, and/or NGS, etc.) will be enrolled in the study to compare the SOC result to results from optical genome mapping.

Other: Standard of care genetic testing group

N/A - no intervention as this is an observational study.

Outcome Measures

Primary Outcome Measures

Sensitivity/Concordance and specificity of OGM with standard of care testing for detection of structural variants. [Through study completion, an average of 1 year]
OGM results are evaluated against the standard of care test and concordance (sensitivity and specificity) will be determined.

Secondary Outcome Measures

Reproducibility and identification of structural variants beyond the limit of detection of standard of care methods. [Through study completion, an average of 1 year]
Inter-site as well as inter and intra-run variability of OGM will be assessed by reproducibility studies.

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Individual with a genomic aberration identified by CMA, karyotyping, Southern blot analysis, PCR, FISH, and/or NGS or other standard of care (SOC) genetic testing technology whose clinical test results are available to compare with results from OGM.
Patients with prior negative SOC genetic testing results whose results are available to compare with results from OGM.

Exclusion Criteria:

Any individual who opted-out of research at the testing laboratory.
An individual whose genetic test contains the following variants: pathogenic sequence variants, abnormalities involving acrocentric p-arms and centromeres, below 20% for mosaicism, and tetraploidy.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Praxis Genomics	Atlanta	Georgia	United States	30328
2	Augusta University Research Institute	Augusta	Georgia	United States	30912
3	University of Iowa Hospitals & Clinics, Molecular Pathology	Iowa City	Iowa	United States	52242
4	Columbia University Irving Medical Center	New York	New York	United States	10032
5	DNA Microarray CGH Laboratory, Department of Pathology, University of Rochester Medical Center	W. Henrietta	New York	United States	14586
6	Greenwood Genetic Center	Greenwood	South Carolina	United States	29646
7	Lineagen (A Bionano Genomics Company)	Salt Lake City	Utah	United States	84109
8	Medical College of Wisconsin	Milwaukee	Wisconsin	United States	53226